# 2025年11月5日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. ICU幸存者出院后新发持续性阿片类药物使用：发生率、预测因素及全国性队列分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184942](https://pubmed.ncbi.nlm.nih.gov/41184942)
**期刊：** Critical care (London, England)
**PMID：** 41184942
**DOI：** 10.1186/s13054-025-05716-w

### 第一部分 原文与翻译

**英文原标题：** New persistent opioid use among ICU survivors after discharge: incidence, predictors, and nationwide cohort analysis.

**英文摘要原文：**
BACKGROUND: Long-term opioid dependence after critical illness is an emerging concern, yet the incidence and predictors of persistent opioid use among intensive care unit (ICU) survivors remain incompletely characterized. We aimed to estimate the six-month incidence of new persistent opioid use in opioid-naïve ICU survivors and to identify associated risk factors.

METHODS: We conducted a retrospective, nationwide cohort study using South Korea's National Health Insurance Service database. Adults admitted to any ICU between January 1, 2020, and December 31, 2022, were included if they survived to hospital discharge and remained alive for at least six months, with no opioid prescription in the 12 months preceding admission. New persistent opioid use was defined as at least one outpatient opioid prescription within 90 days after discharge and at least one additional prescription between 91 and 180 days. We performed multivariable logistic regression to identify independent predictors.

RESULTS: Among 567,260 opioid-naïve ICU survivors, 23,945 (4.2%) developed new persistent opioid use within six months. Across the cohort, 22,643 (4.0%) received less-potent opioids (tramadol, dihydrocodeine) and 1,643 (0.3%) received potent opioids (morphine, fentanyl, oxycodone, hydromorphone, methadone). Independent predictors included older age (odds ratio [OR] 1.01 per year; 95% confidence interval [CI], 1.01-1.02; P < 0.001), female sex (OR 1.13; 95% CI, 1.09-1.16; P < 0.001), socioeconomic disadvantage (Medical Aid, OR 1.30; 95% CI, 1.23-1.38; P < 0.001), malignancy (OR 1.05; 95% CI, 1.01-1.09; P = 0.017), metastatic tumor (OR 1.24; 95% CI, 1.15-1.35; P < 0.001), extracorporeal membrane oxygenation (OR 1.80; 95% CI, 1.75-1.89; P < 0.001), and continuous renal replacement therapy (OR 1.24; 95% CI, 1.11-1.37; P < 0.001). The strongest predictor was an early opioid prescription within 30 days of discharge (OR 19.7; 95% CI, 19.1-20.3; P < 0.001). Potency-specific analysis showed potent opioid persistence was largely driven by cancer, while less-potent use was shaped more by demographic and socioeconomic factors.

CONCLUSIONS: Approximately one in 25 ICU survivors developed new persistent opioid use by six months. Early post-discharge opioid prescription was the dominant risk factor. Risk profiles differed by opioid potency, underscoring the need for early tapering strategies, multimodal non-opioid analgesia, and stewardship programs tailored to patient subgroups and opioid type.

**中文摘要译文：**
背景：危重症后的长期阿片类药物依赖是一个日益引起关注的问题，然而，重症监护室（ICU）幸存者中持续性阿片类药物使用的发生率和预测因素尚未得到完全阐明。本研究旨在评估未使用过阿片类药物的ICU幸存者中，新发持续性阿片类药物使用的六个月发生率，并确定相关的风险因素。

方法：我们利用韩国国民健康保险服务数据库，进行了一项回顾性的全国性队列研究。研究纳入了2020年1月1日至2022年12月31日期间入住任何ICU的成年患者，条件是他们存活至出院，并在此后至少存活六个月，且在入院前12个月内无阿片类药物处方记录。新发持续性阿片类药物使用被定义为：出院后90天内至少有一次门诊阿片类药物处方，并且在第91天至第180天之间至少有一次额外的处方。我们采用多变量逻辑回归分析来确定独立预测因素。

结果：在567,260名未使用过阿片类药物的ICU幸存者中，有23,945人（4.2%）在六个月内出现了新发持续性阿片类药物使用。在整个队列中，22,643人（4.0%）接受了弱效阿片类药物（曲马多，双氢可待因），而1,643人（0.3%）接受了强效阿片类药物（吗啡，芬太尼，羟考酮，氢吗啡酮，美沙酮）。独立预测因素包括：年龄较大（比值比[OR] 1.01/年; 95%置信区间[CI], 1.01-1.02; P < 0.001）、女性（OR 1.13; 95% CI, 1.09-1.16; P < 0.001）、社会经济地位较低（医疗救助，OR 1.30; 95% CI, 1.23-1.38; P < 0.001）、恶性肿瘤（OR 1.05; 95% CI, 1.01-1.09; P = 0.017）、转移性肿瘤（OR 1.24; 95% CI, 1.15-1.35; P < 0.001）、体外膜肺氧合（OR 1.80; 95% CI, 1.75-1.89; P < 0.001）以及连续性肾脏替代治疗（OR 1.24; 95% CI, 1.11-1.37; P < 0.001）。最强的预测因素是出院后30天内的早期阿片类药物处方（OR 19.7; 95% CI, 19.1-20.3; P < 0.001）。针对不同效价的分析显示，强效阿片类药物的持续使用主要由癌症驱动，而弱效阿片类药物的使用更多地受人口统计学和社会经济因素的影响。

结论：大约每25名ICU幸存者中就有1人在六个月内出现新发持续性阿片类药物使用。出院后早期的阿片类药物处方是主要风险因素。不同效价阿片类药物的风险特征各异，这凸显了针对不同患者亚组和阿片类药物类型，制定早期减量策略、多模式非阿片类镇痛方案和药物管理计划的必要性。

### 第二部分 AI 大师评价

本研究基于韩国全国性大数据，精准揭示了约4.2%的ICU幸存者在出院后会产生新的持续性阿片类药物使用。其核心发现指出，出院后30天内的早期处方是风险最高的预测因素，并且强效与弱效阿片类药物的风险画像存在差异，前者多与癌症相关。这项研究的价值在于其规模宏大且数据真实，为临床实践中制定精准的阿片类药物减量策略和管理方案提供了强有力的循证依据，强调了出院后早期干预的极端重要性。

---

## 2. 危重症患者在持续性肾脏替代治疗期间柠檬酸盐蓄积的发生率、严重程度及预测因素。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184940](https://pubmed.ncbi.nlm.nih.gov/41184940)
**期刊：** Critical care (London, England)
**PMID：** 41184940
**DOI：** 10.1186/s13054-025-05691-2

### 第一部分 原文与翻译

**英文原标题：** Incidence, severity, and predictors of citrate accumulation during continuous kidney replacement therapy in the critically ill.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究的核心目的在于系统探究危重症患者在持续性肾脏替代治疗（CKRT）期间，柠檬酸盐蓄积的发生率、严重程度及预测因素。根据标题推断，这可能是一项临床观察性研究，旨在识别导致该并发症的关键风险因子（例如肝功能障碍或休克）。此研究具有显著的临床价值，其成果将帮助临床医生更精准地识别高危患者、优化治疗方案，以预防和管理潜在的代谢紊乱，从而提高CKRT的安全性。由于缺乏摘要，无法深入评估其具体的研究设计与发现。

---

## 3. 送达医院时的心律及自主循环恢复与初始可电击心律的院外心脏骤停患者接受ECPR治疗后预后的关联性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184889](https://pubmed.ncbi.nlm.nih.gov/41184889)
**期刊：** Critical care (London, England)
**PMID：** 41184889
**DOI：** 10.1186/s13054-025-05698-9

### 第一部分 原文与翻译

**英文原标题：** Association of hospital-arrival rhythm and ROSC with outcomes after ECPR for OHCA with initial shockable rhythm.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在探讨对于初始心律为可电击心律的院外心脏骤停（OHCA）患者，在接受体外心肺复苏（ECPR）治疗后，其送达医院时的心律以及是否实现自主循环恢复（ROSC）与临床预后的关联。本研究聚焦于ECPR这一前沿且资源密集型技术的关键预后因素，对于优化患者筛选标准、指导临床决策具有重要价值。其发现可能有助于识别哪些患者最有可能从ECPR中获益，从而更有效地分配医疗资源，并可能改善这类危重患者的生存率和神经功能恢复。

---

## 4. 呼吸相关皮层激活与机械通气撤机的关联：一项生理学研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184870](https://pubmed.ncbi.nlm.nih.gov/41184870)
**期刊：** Critical care (London, England)
**PMID：** 41184870
**DOI：** 10.1186/s13054-025-05706-y

### 第一部分 原文与翻译

**英文原标题：** Association between respiratory-related cortical activation and weaning from mechanical ventilation: a physiological study.

**英文摘要原文：**
BACKGROUND: In mechanically ventilated patients, extubation is decided after passing a spontaneous breathing trial (SBT). Supplementary motor area, which can be non-invasively assessed by measuring amplitude of pre-inspiratory potentials (PIPs), is recruited in case of increased respiratory effort. Weaning failure may be accompanied by increased respiratory effort. We hypothesized that early increased PIP amplitude from the start of SBT may be associated with SBT failure.

PATIENTS AND METHODS: We performed a single-center physiological prospective study in mechanically ventilated patients meeting weaning criteria. PIP amplitude was measured using electroencephalography under mechanical ventilation and then during the first 15-min of the SBT performed using a T-piece. We compared respiratory-related cortical activation between patients who passed a 1-h SBT and those who failed.

RESULTS: Among the 62 patients included, 17 (27%) failed the SBT. Whereas patients who failed the SBT had a lower median amplitude of PIPs under mechanical ventilation than those who passed the SBT (0.6 µV [IQR, 0-1.3] vs. 1.9 [1.2-2.9], p < 0.0001), they had a higher amplitude of PIPs at the beginning of the SBT (2.1 µV [IQR, 1.7-2.9] vs. 1.2 [0.5-2.0], p < 0.005). PIP amplitude between mechanical ventilation and SBT significantly increased in case of SBT failure whereas it decreased in case of SBT success (+ 1.7 µV [1.2-2.1] vs. -0.5 [-1.8-0.1], p < 0.0001). An increase of PIP above 0.43 µV was associated with SBT failure with sensitivity of 100% and specificity of 87%.

CONCLUSION: The demonstration of an association between increased respiratory-related cortical activation and failure of the weaning trial is a physiological marker of interest for better phenotyping of patients ready for weaning.

**中文摘要译文：**
背景：对于机械通气患者，拔管决策于自主呼吸试验（SBT）成功后做出。在呼吸努力增加时，辅助运动区会被激活，该区域的活动可通过无创测量吸气前电位（PIPs）的振幅来评估。撤机失败可能伴随着呼吸努力的增加。我们假设，在SBT开始时PIPs振幅的早期升高可能与SBT失败相关。

患者与方法：我们对符合撤机标准的机械通气患者进行了一项单中心生理学前瞻性研究。我们使用脑电图测量了患者在机械通气期间以及在使用T管进行SBT的前15分钟内的PIPs振幅。我们比较了通过1小时SBT的患者与失败患者之间呼吸相关的皮层激活情况。

结果：在纳入的62名患者中，17名（27%）SBT失败。SBT失败的患者在机械通气下的PIPs振幅中位数低于SBT成功的患者（0.6 µV [IQR, 0-1.3] vs. 1.9 [1.2-2.9], p < 0.0001），但在SBT开始时其PIPs振幅却更高（2.1 µV [IQR, 1.7-2.9] vs. 1.2 [0.5-2.0], p < 0.005）。在SBT失败的情况下，从机械通气到SBT期间的PIPs振幅显著增加，而在SBT成功的情况下则降低（+ 1.7 µV [1.2-2.1] vs. -0.5 [-1.8-0.1], p < 0.0001）。PIPs振幅增加超过0.43 µV与SBT失败相关，其敏感性为100%，特异性为87%。

结论：本研究证实了呼吸相关皮层激活增加与撤机试验失败之间的关联，这为更精准地对准备撤机的患者进行表型分层提供了一个有价值的生理学标志物。

### 第二部分 AI 大师评价

本研究旨在探索呼吸相关的皮层激活（通过吸气前电位PIPs测量）与机械通气患者撤机过程中自主呼吸试验（SBT）成败的关联。研究创新性地采用脑电图（EEG）无创监测SBT期间大脑辅助运动区的活动变化，发现SBT失败患者的PIPs振幅在从机械通气转换至SBT期间显著升高，而成功者则相反。该研究不仅揭示了撤机失败背后可能存在的中枢神经驱动过度激活的生理机制，更重要的是，提供了一个高度敏感和特异的预测指标（PIPs振幅变化 > 0.43 µV），为临床早期识别高风险撤机失败患者、实现更精准的患者分型和撤机决策提供了新的生理学依据。

---

## 5. 线粒体损伤驱动重大手术后台T细胞的免疫代谢麻痹

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184637](https://pubmed.ncbi.nlm.nih.gov/41184637)
**期刊：** EMBO molecular medicine
**PMID：** 41184637
**DOI：** 10.1038/s44321-025-00324-1

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial damage drives T-cell immunometabolic paralysis after major surgery.

**英文摘要原文：**
Cytotoxic T cell (CTL) dysfunction is a hallmark of immune paralysis after major surgery, increasing susceptibility to severe nosocomial infections and contributing to mortality in critically ill patients. The mechanisms remain poorly understood. We demonstrate that reactive oxygen species (ROS) released by myeloid-derived suppressor cells (MDSC) transiently emerging after surgery, drive perioperative CTL immunoparalysis. These ROS damage CTL mitochondria, triggering secondary mitochondrial ROS amplification and overwhelming antioxidant defenses. The resulting oxidative cascade impairs oxidative phosphorylation and suppresses CTL effector function. Concurrently, stress-induced mitochondrial hyperfusion disrupts fission-dependent translocation to the immunological synapse, exacerbating bioenergetic failure. MitoTEMPO, a mitochondria-targeted antioxidant, partially mitigates these effects, highlighting mitochondrial stabilization as a potential strategy to prevent perioperative immune dysfunction.

**中文摘要译文：**
细胞毒性T细胞（CTL）功能障碍是重大手术后免疫麻痹的一个标志，它增加了对严重院内感染的易感性，并导致危重症患者死亡率的上升。其具体机制仍不甚明了。我们证明，由术后短暂出现的髓源性抑制细胞（MDSC）释放的活性氧（ROS）驱动了围手术期CTL的免疫麻痹。这些活性氧会损伤CTL的线粒体，引发继发性的线粒体活性氧扩增，并压垮抗氧化防御系统。由此产生的氧化级联反应损害了氧化磷酸化过程，并抑制了CTL的效应功能。同时，应激诱导的线粒体过度融合破坏了依赖于分裂的向免疫突触的转运，从而加剧了生物能学衰竭。线粒体靶向抗氧化剂MitoTEMPO能够部分缓解这些效应，这凸显了稳定线粒体作为一种预防围手术期免疫功能障碍的潜在策略。

### 第二部分 AI 大师评价

本研究旨在揭示重大手术后T细胞功能障碍的核心机制。研究发现，术后短暂出现的髓源性抑制细胞（MDSC）释放的活性氧（ROS）是关键诱因，它直接损伤T细胞的线粒体，不仅破坏了其能量代谢，还干扰了其动态平衡，最终导致T细胞免疫麻痹。该研究的创新之处在于精准定位了“MDSC-ROS-线粒体损伤”这一关键通路，为理解术后免疫抑制提供了新的分子视角，并提示了靶向稳定线粒体（如使用MitoTEMPO）作为预防和治疗围手术期免疫功能障碍的潜在临床策略，具有重要的转化价值。

---

## 6. COVID-19相关ARDS后肺纤维化改变的ICU预测因素：一项RECOVIDS亚组研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184594](https://pubmed.ncbi.nlm.nih.gov/41184594)
**期刊：** Annals of intensive care
**PMID：** 41184594
**DOI：** 10.1186/s13613-025-01577-2

### 第一部分 原文与翻译

**英文原标题：** ICU predictive factors of fibrotic changes following COVID-19 related ARDS: a RECOVIDS substudy.

**英文摘要原文：**
BACKGROUND: Pulmonary fibrotic changes (FC) following COVID-19-related ARDS represent a significant concern due to the potential respiratory complications. The identification of early predictive factors for FC and the development of predictive tools are needed to optimize patient management and outcomes.

METHODS: This observational prospective multicentre study is a substudy of the RECOVIDS study and included 32 centres in France and Belgium. COVID-19 ARDS survivors were included if they met the Berlin ARDS criteria or if they received high flow oxygen therapy (flow ≥ 50 L/min and FiO ≥ 50%). Exclusion criteria were non-attendance at follow-up 6 ± 1 months after ICU discharge, lack of baseline or follow-up chest CT, and history of interstitial lung disease. The primary endpoint was presence of FC at follow-up CT. The secondary outcome was to identify predominant radiological patterns.

RESULTS: Among 555 patients included in the RECOVIDS study, 440 were analysed, of whom 162 (36.8%) had FC at follow-up. Predictive factors for FC included older age, body mass index < 30, Charlson comorbidity index ≥ 1, invasive mechanical ventilation, early signs of FC, and greater lung involvement on baseline CT. The nomogram for predicting pulmonary FC yielded an AUC of 80.6% (95%CI (76.4-84.8)). Late organizing pneumonia was the most common pattern overall and 30 (18.5%) of the 162 patients with FC presented mainly anterior fibrosis compatible with post ventilatory changes.

CONCLUSION: In this large cohort of COVID-19 ARDS survivors, 36.8% exhibited FC at 6 months post-ICU discharge. The key predictors identified here could guide therapeutic and follow-up strategies.

**中文摘要译文：**
背景：COVID-19相关ARDS后的肺纤维化改变（FC）因其潜在的呼吸系统并发症而备受关注。识别FC的早期预测因素并开发预测工具有助于优化患者管理和改善预后。

方法：这项观察性、前瞻性、多中心研究是RECOVIDS研究的一项亚组研究，纳入了法国和比利时的32个中心。研究纳入了符合ARDS柏林标准或接受高流量氧疗（流量≥50升/分钟且吸入氧浓度≥50%）的COVID-19 ARDS幸存者。排除标准包括ICU出院后6±1个月未参加随访、缺少基线或随访胸部CT扫描，以及有间质性肺病史。主要终点是随访CT上出现FC。次要结局是确定主要的影像学模式。

结果：在RECOVIDS研究纳入的555名患者中，440名被纳入分析，其中162名（36.8%）在随访中出现FC。FC的预测因素包括年龄较大、体重指数<30、Charlson合并症指数≥1、有创机械通气、早期FC迹象以及基线CT显示更广泛的肺部受累。用于预测肺部FC的列线图AUC为80.6% (95%CI (76.4-84.8))。晚期机化性肺炎是总体上最常见的模式，在162名FC患者中，有30名（18.5%）主要表现为与通气后改变相符的前部纤维化。

结论：在这个大型COVID-19 ARDS幸存者队列中，36.8%的患者在ICU出院后6个月表现出FC。本研究识别出的关键预测因素可为治疗和随访策略提供指导。

### 第二部分 AI 大师评价

本研究旨在识别COVID-19相关ARDS幸存者发生肺纤维化改变（FC）的早期预测因素。通过一项大规模、前瞻性多中心研究，作者发现近37%的患者在ICU出院6个月后出现FC，并确定了高龄、较低的体重指数、合并症、有创通气及基线肺部受累程度等关键风险因素。该研究的价值在于构建了一个预测性能良好（AUC > 80%）的列线图模型，为临床早期筛选高危人群、指导后续治疗与随访策略提供了重要依据，具有显著的临床转化潜力。

---

## 7. 基于临床可穿戴设备的深度学习院内病情持续恶化预测模型的开发与验证

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184270](https://pubmed.ncbi.nlm.nih.gov/41184270)
**期刊：** Nature communications
**PMID：** 41184270
**DOI：** 10.1038/s41467-025-65219-8

### 第一部分 原文与翻译

**英文原标题：** Development and validation of a clinical wearable deep learning based continuous inhospital deterioration prediction model.

**英文摘要原文：**
Standard episodic patient monitoring of vital signs on the medical-surgical wards can potentially miss changes in health status and delay recognition of risk. To reduce these delays, we develop a clinical wearable-based deep learning model, using 9 inputs, comprised of continuous vital signs and demographics, to identify the onset of deterioration early and accurately. Using validated data from 888 adult non-intensive care unit inpatient visits with 135 outcomes, from two different clinical grade wearables, we train a recurrent neural network to predict clinical alerts and adverse clinical outcomes in the subsequent 24 hours. Our continuous clinical alert model is able to predict both clinical alerts (Area under both the Receiver Operator Characteristic curve 0.89 + /- 0.3, Precision Recall curve 0.58 + /- 0.14) and adverse clinical outcomes (accuracy: 81.8% on 11 events) up to 17 hours in advance. Our wearable based continuous clinical alert system outperforms episodic clinical support tools in detecting deterioration, retains its performance when tested on data from a different clinical wearable than the one it was trained on and can produce alerts ahead of a broad class of adverse clinical outcomes, enabling timely interventions that can avert preventable deteriorations and reduce hospital costs.

**中文摘要译文：**
内外科病房对生命体征的常规间断性患者监测可能会错过健康状况的变化，并延迟风险识别。为减少这些延迟，我们开发了一种基于临床可穿戴设备的深度学习模型，该模型使用包含连续生命体征和人口统计学信息在内的9项输入，以早期且准确地识别病情恶化的发生。我们使用来自两种不同临床级可穿戴设备的、经核验的数据（涵盖888名非重症监护室成年住院患者的就诊记录及135例结局事件），训练了一个递归神经网络来预测未来24小时内的临床警报和不良临床结局。我们的持续性临床警报模型能够预测临床警报（受试者工作特征曲线下面积为0.89±0.3，精确率-召回率曲线为0.58±0.14）和不良临床结局（在11个事件上的准确率为81.8%），且最多可提前17小时。我们基于可穿戴设备的持续性临床警报系统在检测病情恶化方面优于间断性的临床支持工具，当使用未经训练的不同临床可穿戴设备数据进行测试时仍能保持其性能，并能在一系列广泛的不良临床结局发生前发出警报，从而实现及时的干预，避免可预防的病情恶化并降低医院成本。

### 第二部分 AI 大师评价

本研究旨在解决传统间断性生命体征监测可能延误发现患者病情恶化的关键问题。研究团队创新性地利用临床级可穿戴设备采集连续生命体征数据，并构建了一个深度学习模型来提前预测非ICU住院患者的病情恶化。其核心发现是该模型能提前长达17小时准确预警，且在不同设备间表现出良好的泛化能力，显著优于传统的临床支持工具。这项研究展示了可穿戴技术与人工智能结合在主动式患者监护中的巨大潜力，为实现早期干预、提升医疗质量和降低成本提供了重要实证。

---

## 8. ICU获得性衰弱管理的重症医学研究议程：一项多国、跨专业的视角

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182389](https://pubmed.ncbi.nlm.nih.gov/41182389)
**期刊：** Intensive care medicine
**PMID：** 41182389
**DOI：** 10.1007/s00134-025-08186-4

### 第一部分 原文与翻译

**英文原标题：** The intensive care medicine research agenda for the management of ICU acquired weakness: a multinational, interprofessional perspective.

**英文摘要原文：**
Intensive care unit acquired weakness (ICUAW) is common in critically ill patients, contributing to substantial morbidity. Major trials and novel mechanistic findings published over the past years have advanced knowledge for the prevention and treatment of ICUAW. To streamline future research priorities, a multinational, interdisciplinary group of ICU clinicians, researchers, and people with lived experience convened to develop this evidence-based research agenda. Using a stepwise process including a systematic review with meta-analysis, two expert panel meetings, and a two-round modified Delphi method, we identified the top ten research priorities for ICUAW. Our report highlights the lack of reliable prognostic markers and mechanistic understanding that limit early diagnosis and treatment. Current evidence to treat ICUAW supports enhanced physical rehabilitation versus no rehabilitation, while higher dose enterally-delivered protein alone does not improve patient outcomes. However, the direct effects on muscles or appropriate dosing for patients with comorbidities remain largely unknown. The proposed ten key priority research questions integrate pathophysiology, diagnostics, treatment, and follow-up and emphasise personalised medicine and patient-centred outcomes over the continuum of recovery. Future research should focus on early prognostic markers, mechanisms of ICUAW, and identification of treatment responders allowing individualised dosing strategies tailored across the recovery trajectory. Defining meaningful outcomes, improving follow-up care, and integrating patient, family and caregiver priorities are essential. Advancing this agenda will require interdisciplinary collaboration and the use of emerging methods, including artificial intelligence, to support personalised and effective ICUAW care.

**中文摘要译文：**
重症监护室获得性衰弱（ICUAW）在危重症患者中很常见，是导致显著发病率的重要原因。过去几年发表的重大试验和新的机制性发现，增进了我们对ICUAW预防和治疗的认识。为了明确未来的研究重点，一个由ICU临床医生、研究人员和亲身经历者组成的多国、跨学科小组共同制定了这一循证研究议程。通过包括系统评价与荟萃分析、两次专家小组会议以及两轮改良德尔菲法在内的分步流程，我们确定了ICUAW的十大优先研究方向。我们的报告强调，目前缺乏可靠的预后标志物和对机制的深入理解，这限制了早期诊断和治疗。当前治疗ICUAW的证据支持强化物理康复（相对于不康复），而单独通过肠内途径提供更高剂量的蛋白质并不能改善患者结局。然而，其对肌肉的直接影响或针对合并症患者的合适剂量在很大程度上仍是未知的。所提出的十个关键优先研究问题整合了病理生理学、诊断、治疗和随访，并强调在整个康复过程中实施个性化医疗和以患者为中心的结局。未来的研究应侧重于早期预后标志物、ICUAW的发生机制，以及识别治疗应答者，以便在整个康复轨迹中量身定制个体化的给药策略。定义有意义的结局、改善随访护理，并整合患者、家属和照护者的优先事项至关重要。推进这一研究议程将需要跨学科合作，并利用包括人工智能在内的新兴方法，以支持个性化和有效的ICUAW护理。

### 第二部分 AI 大师评价

本研究通过系统性回顾、专家会议及德尔菲法，汇集了多国跨专业团队（包括患者）的智慧，旨在为ICU获得性衰弱（ICUAW）领域确立十大优先研究方向。其核心发现指出现有研究在早期预后标志物、病理机制理解及个体化治疗方面存在显著空白。该研究的创新性在于其严谨的多方共识方法和对患者视角的整合，为全球研究者提供了极具价值的路线图，有望引导未来的科研资源投向最关键的临床问题，从而推动ICU康复领域的精准化与人性化发展。

---

## 9. 危重症成年患者气道管理的最佳实践

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182388](https://pubmed.ncbi.nlm.nih.gov/41182388)
**期刊：** Intensive care medicine
**PMID：** 41182388
**DOI：** 10.1007/s00134-025-08181-9

### 第一部分 原文与翻译

**英文原标题：** Best practices in airway management in critically ill adults.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

鉴于原文暂无摘要，根据其标题推断，本文献可能是一篇关于危重症成年患者气道管理的临床实践指南或专家共识。该文的核心目的在于系统性整合该领域的最新研究证据和临床经验，为气道管理这一高风险操作提供一套标准化的最佳实践流程。其临床价值巨大，旨在指导重症监护医师、急诊医师及麻醉医师在紧急情况下做出快速、准确的决策，从而提高插管成功率，降低相关并发症风险，对改善患者预后具有重要的指导意义。

---

## 10. 澳大利亚和新西兰成年重症患者脓毒症与脓毒性休克的死亡率趋势

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182386](https://pubmed.ncbi.nlm.nih.gov/41182386)
**期刊：** Intensive care medicine
**PMID：** 41182386
**DOI：** 10.1007/s00134-025-08162-y

### 第一部分 原文与翻译

**英文原标题：** Mortality trends for sepsis and septic shock among critically ill adults in Australia and New Zealand.

**英文摘要原文：**
PURPOSE: Sepsis is a major cause of mortality in intensive care unit (ICU) patients. Significant temporal improvements in survival were observed in Australia and New Zealand (ANZ) from 2000 to 2012. Whether this has continued remains uncertain, and current sepsis-related mortality in ANZ ICUs is unknown.

METHODS: We studied adult ICU patients admitted with sepsis (based on the 3rd international consensus definition for sepsis and septic shock), between January 2000 and June 2023. Data were obtained from 219 ICUs that contributed to the ANZ Intensive Care Society Adult Patient Database. We used logistic regression models to study changes in in-hospital mortality over time.

RESULTS: Among 2,975,149 ICU admissions, 303,389 patients had sepsis. In-hospital mortality was 28% in 2000, falling to 13% in 2023 (adjusted OR 0.48; 95% confidence interval [CI] 0.43 to 0.54). Mortality decreased at a rate of 1.1% per year between 2000-2013, 0.3% per year between 2013-2020 (p < 0.001 for change in slope), and increased 0.9% per year between 2020-2023 (p < 0.001). A nadir of 11% was observed in 2020. Modelled linearly, in-hospital mortality decreased 4% per year from 2000 to 2020, independent of measurable confounding. Contemporary in-hospital mortality was 25% in those with septic shock, and 20% in those receiving invasive mechanical ventilation.

CONCLUSIONS: In-hospital mortality in adult ANZ ICU patients admitted with sepsis decreased significantly from 28% in 2000 to a nadir of 11% in 2020, independent of changes in case-mix. In-hospital mortality remains substantially higher with septic shock and in those receiving invasive mechanical ventilation.

**中文摘要译文：**
目的：脓毒症是重症监护室（ICU）患者死亡的主要原因。2000年至2012年间，澳大利亚和新西兰（ANZ）观察到患者生存率随时间有显著改善。此趋势是否持续尚不确定，且ANZ地区ICU当前与脓毒症相关的死亡率未知。

方法：我们研究了2000年1月至2023年6月期间因脓毒症（基于第三版脓毒症与脓毒性休克国际共识定义）入住ICU的成年患者。数据来源于219家为澳新重症监护学会成人患者数据库提供数据的ICU。我们采用logistic回归模型研究院内死亡率随时间的变化。

结果：在2,975,149例ICU入院患者中，303,389例患有脓毒症。院内死亡率从2000年的28%下降至2023年的13%（调整后比值比[OR] 0.48；95%置信区间[CI] 0.43至0.54）。2000-2013年间，死亡率以每年1.1%的速度下降；2013-2020年间，以每年0.3%的速度下降（斜率变化p < 0.001）；而在2020-2023年间，则以每年0.9%的速度上升（p < 0.001）。2020年观察到死亡率最低点为11%。线性模型显示，从2000年到2020年，院内死亡率每年下降4%，且不受可测量的混杂因素影响。当前，脓毒性休克患者的院内死亡率为25%，接受有创机械通气的患者为20%。

结论：在因脓毒症入住ANZ地区ICU的成年患者中，院内死亡率从2000年的28%显著下降至2020年的最低点11%，且此变化独立于病例组合的改变。对于脓毒性休克和接受有创机械通气的患者，其院内死亡率仍然显著更高。

### 第二部分 AI 大师评价

该研究是一项基于澳新地区大型多中心数据库的大规模、长周期回顾性队列研究，旨在探究过去二十余年成年重症脓毒症患者的死亡率动态变化。其核心发现揭示了死亡率从2000年至2020年持续显著下降，但此后出现小幅回升的转折点，为评估区域性脓毒症管理成效提供了宝贵的宏观数据。此研究不仅更新了关键的流行病学证据，也为临床医生和卫生政策制定者指出了未来需关注的挑战，尤其是在疫情后时代背景下，具有重要的临床指导和公共卫生价值。

---

## 11. 如何预防术后急性肾损伤？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182384](https://pubmed.ncbi.nlm.nih.gov/41182384)
**期刊：** Intensive care medicine
**PMID：** 41182384
**DOI：** 10.1007/s00134-025-08193-5

### 第一部分 原文与翻译

**英文原标题：** How to prevent acute kidney injury postoperatively?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文标题揭示了其核心目的，即系统性地探讨术后急性肾损伤（AKI）的预防策略。由于没有提供摘要，可以推断这可能是一篇综述、指南或专家评论，而非原创性研究。该文很可能整合了当前关于术后AKI风险评估、围术期血流动力学优化、肾毒性药物规避及新型干预措施的临床证据。尽管缺乏具体的研究方法和数据，但其临床价值在于为重症监护和外科医生提供了一个关于预防术后AKI的实用框架和知识更新，对指导临床实践具有重要意义。

---

## 12. 超越统计学异质性：脓毒性休克复苏中的生理学个体化治疗。作者的答复。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41182382](https://pubmed.ncbi.nlm.nih.gov/41182382)
**期刊：** Intensive care medicine
**PMID：** 41182382
**DOI：** 10.1007/s00134-025-08184-6

### 第一部分 原文与翻译

**英文原标题：** Beyond statistical heterogeneity: physiological individualization in septic shock resuscitation. Authors' Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇“作者答复”，旨在回应关于脓毒性休克复苏中个体化治疗的讨论。文章标题鲜明地提出，应超越传统临床试验中的统计学异质性，转而关注基于患者具体生理状况的个体化复苏策略。此观点强调了在脓毒性休克这一高度异质性疾病中，精准医疗的重要性，推动了从“一刀切”方案向“量体裁衣”治疗模式的转变。尽管作为一篇答复性文章，它不包含原创研究数据，但其深刻的学术思辨对于启发未来临床研究设计和优化重症监护实践具有重要的指导意义。

---

## 13. 创伤性脑损伤后脑血管单元的激活与反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166163](https://pubmed.ncbi.nlm.nih.gov/41166163)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 41166163
**DOI：** 10.1097/SHK.0000000000002736

### 第一部分 原文与翻译

**英文原标题：** Cerebrovascular Unit Activation and Response Following Traumatic Brain Injury.

**英文摘要原文：**
Traumatic brain injury (TBI) is a significant cause of death and disability, affecting nearly 300,000 Americans annually. Beyond the immediate physical damage, TBI induces chronic neuroinflammation and long-term neurodegeneration, leading to various neurologic and psychiatric disorders. This review examines the cerebrovascular unit (CVU), particularly the cerebral endothelial cells, and their critical role in the aftermath of TBI. Following TBI, the CVU undergoes functional changes to counteract inflammation, repair endothelial damage, and promote angiogenesis. However, dysregulation of these protective mechanisms can lead to chronic neuroinflammation, increased cerebrovascular permeability, and systemic endothelial dysfunction. The review explores the molecular and cellular responses of the CVU following TBI, highlighting the roles of inflammatory cytokines, oxidative stress, and various endothelial transport mechanisms. Moreover, TBI-related endothelial dysfunction may extend beyond the brain, potentially contributing to systemic complications such as acute respiratory distress syndrome (ARDS) and multisystem organ failure. Despite the gravity of these conditions, clinical breakthroughs remain limited. This review underscores the necessity for targeted therapeutic strategies to mitigate endothelial dysfunction and improve long-term outcomes for TBI patients. Future research is essential to elucidate the precise mechanisms driving CVU dysfunction and to develop interventions that can alleviate the chronic effects of TBI.

**中文摘要译文：**
创伤性脑损伤（TBI）是导致死亡和残疾的重要原因，每年影响近30万美国人。除了直接的物理损伤外，TBI还会引发慢性神经炎症和长期神经退行性病变，导致多种神经系统和精神系统疾病。这篇综述探讨了脑血管单元（CVU），特别是脑内皮细胞，及其在TBI发生后的关键作用。TBI后，CVU会发生功能性改变，以对抗炎症、修复内皮损伤并促进血管生成。然而，这些保护机制的失调可能导致慢性神经炎症、脑血管通透性增加和全身性内皮功能障碍。该综述探讨了TBI后CVU的分子和细胞反应，重点阐述了炎性细胞因子、氧化应激以及多种内皮转运机制的作用。此外，与TBI相关的内皮功能障碍可能超出脑部范围，可能导致急性呼吸窘迫综合征（ARDS）和多系统器官衰竭等全身性并发症。尽管这些情况非常严重，但临床上的突破仍然有限。这篇综述强调了采取靶向治疗策略以减轻内皮功能障碍、改善TBI患者长期预后的必要性。未来的研究对于阐明驱动CVU功能障碍的精确机制以及开发能够缓解TBI慢性影响的干预措施至关重要。

### 第二部分 AI 大师评价

本综述系统阐述了创伤性脑损伤（TBI）后脑血管单元（CVU）的关键病理生理角色，特别是脑内皮细胞的功能改变。文章深入探讨了TBI如何引发内皮功能障碍，进而导致慢性神经炎症、血管通透性增加乃至全身性并发症。该文的价值在于整合了TBI研究中关于血管反应的现有知识，强调了将内皮功能障碍作为治疗靶点的重要性，为开发旨在改善TBI患者长期预后的新策略指明了方向。

---

## 14. 优化人类休克的临床前啮齿类动物研究模型：第一部分 腹腔内脓毒症

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166157](https://pubmed.ncbi.nlm.nih.gov/41166157)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 41166157
**DOI：** 10.1097/SHK.0000000000002742

### 第一部分 原文与翻译

**英文原标题：** Optimization of Pre-Clinical Rodent Research Models of Human Shock: Part 1 Intra-abdominal Sepsis.

**英文摘要原文：**
Preclinical models using animals are crucial for medical advancements despite their limitations and criticisms. Critical illnesses like sepsis, trauma, and burns remain huge causes of morbidity and mortality despite medical advances, and human studies may not always be feasible. In this part 1 of 2 reviews about animal models for critical illness, we discuss sepsis and the considerations one should take to optimize the rodent sepsis model. There are multiple models of sepsis used, each with advantages and disadvantages and they can be modified to reflect how patients are treated in the hospital, including intensive care unit care. Patient factors like age, sex, and comorbidities are important considerations given the different responses to sepsis. Aspects of sepsis that our patients encounter including muscle and neurocognitive dysfunction can be modeled to try and improve those aspects of outcomes. Choosing the right models for the question one is asking and optimizing that model is key to recapitulate the human condition to make animal models more translatable to humans. In other words, we suggest that, in lieu of abandoning animal models of sepsis, we seek to enhance translatability to the human condition.

**中文摘要译文：**
尽管存在局限性和批评，但使用动物的临床前模型对于医学进步至关重要。尽管医学取得了进步，脓毒症、创伤和烧伤等危重疾病仍然是发病和死亡的主要原因，而且人体研究并非总是可行。在这篇关于危重疾病动物模型的两部分综述的第一部分中，我们讨论了脓毒症以及优化啮齿类动物脓毒症模型时应考虑的因素。目前使用的脓毒症模型有多种，各有优缺点，并且可以进行修改以反映患者在医院（包括重症监护室）的治疗方式。考虑到对脓毒症的不同反应，年龄、性别和合并症等患者因素是重要的考虑因素。我们的患者所遇到的脓毒症的各个方面，包括肌肉和神经认知功能障碍，都可以通过建模来尝试改善这些方面的结局。为所要研究的问题选择正确的模型并对其进行优化，是重现人类状况、使动物模型更具向人类转译潜力的关键。换言之，我们建议，我们不应放弃脓毒症动物模型，而应寻求增强其向人类状况转译的能力。

### 第二部分 AI 大师评价

本篇综述的核心目的在于探讨如何优化腹腔内脓毒症的临床前啮齿类动物模型，以更好地模拟人类疾病状态。文章总结了现有脓毒症模型的优缺点，并强调了在模型设计中整合患者因素（如年龄、性别、合并症）和临床相关结局（如肌肉与神经认知功能障碍）的重要性。该综述并非否定动物模型的价值，而是倡导通过精细化优化来提升其临床转化潜力，为脓毒症等危重疾病的基础研究提供了重要的方向性指导，对弥合基础与临床研究间的鸿沟具有积极意义。

---

## 15. 脓毒症休克危重患者中不同硫胺素给药策略的比较

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166064](https://pubmed.ncbi.nlm.nih.gov/41166064)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 41166064
**DOI：** 10.1097/SHK.0000000000002739

### 第一部分 原文与翻译

**英文原标题：** Comparison of Variable Thiamine Dosing Strategies in Critically Ill Patients with Septic Shock.

**英文摘要原文：**
BACKGROUND: Thiamine has been utilized for metabolic resuscitation in septic shock (SS), but optimal thiamine dosing remains unknown. The purpose of this study was to assess variable thiamine dosing in critically ill patients with SS.

METHODS: This retrospective, cohort study included SS patients on high dose (HD >500 mg/day) or low dose (LD ≤500 mg/day) thiamine for 72 hours without an alternative indication. The primary endpoint was to evaluate the impact of HD or LD thiamine on vasopressor alive-and-free days.

RESULTS: The analysis included 87 patients that received HD thiamine and 65 patients that received LD thiamine. The mean thiamine dose was 1485.6 mg/day in the HD group and 323.8 mg/day in the LD group. The HD group utilized more 30 mL/kg of intravenous fluid resuscitation (89% vs 82%) and hydrocortisone at 300 mg/day (69% vs 58%). Results found vasopressor alive-and-free days to be 17.13 in the HD group and 14.84 days in the LD group. No statistically discernible differences between the groups in 28-day mortality, ICU length of stay, vasopressor free days, percentage decrease in lactate or serum creatinine, need for additional vasopressor(s), or hospital length of stay were found, although some of the observed differences are believed to be clinically meaningful.

CONCLUSION AND RELEVANCE: Patients with SS that received HD thiamine had no statistically discernible differences in vasopressor alive-and-free days or ICU length of stay as compared to the LD thiamine group. Larger, prospective, randomized trials are warranted to further investigate HD thiamine in critically ill patients with SS.

**中文摘要译文：**
背景：硫胺素已被用于脓毒症休克（SS）的代谢复苏，但最佳硫胺素剂量仍然未知。本研究旨在评估不同硫胺素剂量对SS危重患者的影响。

方法：本回顾性队列研究纳入了接受大剂量（HD >500毫克/天）或小剂量（LD ≤500毫克/天）硫胺素治疗72小时且无其他用药指征的SS患者。主要终点是评估大剂量或小剂量硫胺素对“无血管升压药生存天数”的影响。

结果：分析共纳入87名接受大剂量硫胺素治疗的患者和65名接受小剂量硫胺素治疗的患者。大剂量组的平均硫胺素剂量为1485.6毫克/天，小剂量组为323.8毫克/天。大剂量组更多地接受了30毫升/公斤的静脉输液复苏（89% vs 82%）和300毫克/天的氢化可的松治疗（69% vs 58%）。结果显示，大剂量组的无血管升压药生存天数为17.13天，小剂量组为14.84天。尽管研究者认为某些观察到的差异具有临床意义，但在28天死亡率、ICU住院时长、无血管升压药天数、乳酸或血清肌酐下降百分比、额外血管升压药需求或住院总时长方面，两组间未发现统计学上可辨别的差异。

结论与相关性：与小剂量硫胺素组相比，接受大剂量硫胺素治疗的SS患者在无血管升压药生存天数或ICU住院时长方面没有统计学上可辨别的差异。未来有必要开展更大规模的前瞻性随机试验，以进一步研究大剂量硫胺素在SS危重患者中的应用。

### 第二部分 AI 大师评价

该研究通过一项回顾性队列分析，旨在探讨脓毒症休克危重患者中，大剂量与小剂量硫胺素治疗策略的差异。研究核心发现，尽管大剂量组在“无血管升压药生存天数”上表现出一定优势趋势，但两组在主要终点及多数次要终点上均未达到统计学显著性差异。这项研究的价值在于，它针对临床实践中一个常见但缺乏共识的问题（硫胺素的最佳剂量）提供了初步的真实世界证据，并明确指出了未来需要通过更大规模、设计更严谨的前瞻性随机对照试验来进一步验证和探索。

---

## 16. 致命性出血的处理：重症监护临床试验专家（3CT）研讨会的经验应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41144948](https://pubmed.ncbi.nlm.nih.gov/41144948)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 41144948
**DOI：** 10.1097/SHK.0000000000002735

### 第一部分 原文与翻译

**英文原标题：** Management of life-threatening bleeding: Application of Learned Experiences from the Critical Care Clinical Trialists (3CT) Workshop.

**英文摘要原文：**
Resume: Mortality from major bleeding in trauma patients is highest within the first six hours post-injury. Advances in patient management, driven by national guidelines and clinical trials, have significantly improved outcomes. However, variability in patient profiles, clinical presentations, and standard care practices complicates the assessment of treatment efficacy in clinical trials. In June 2024, international experts convened at the Critical Care Clinical Trialists (3CT) Workshop to examine the evolution of massive bleeding management and the impact of patient and treatment heterogeneity on trial design. This opinion article builds on the workshop discussions and underscores key considerations for the interpretation of large-scale studies. Three main conclusions emerged: First, the need for standardized definitions of "massive bleeding," "life-threatening bleeding," and "massive transfusion" to ensure consistent patient classification and treatment strategies. Second, the importance of tailored approaches that account for patient heterogeneity, including the careful selection of target populations and the use of appropriate primary endpoints. Third, the necessity of methodological adaptations in emergency research settings, such as implementing deferred consent procedures, conducting interim analyses, and using automated adjudication systems to improve objectivity and trial efficiency. In summary, harmonizing terminology, embracing clinical diversity, and refining trial design are essential to enhance the quality, comparability, and clinical relevance of research in massive bleeding. These measures ultimately aim to improve outcomes for critically bleeding patients.

**中文摘要译文：**
创伤患者大出血的死亡率在伤后六小时内最高。在国家指南和临床试验的推动下，患者管理方面的进步已显著改善了预后。然而，患者特征、临床表现和标准护理实践的差异性，使得临床试验中治疗效果的评估变得复杂。2024年6月，国际专家齐聚重症监护临床试验专家（3CT）研讨会，探讨大出血管理的发展以及患者和治疗异质性对试验设计的影响。这篇观点文章基于研讨会的讨论，并强调了解读大型研究的关键考量因素。会议得出三点主要结论：首先，需要对“大出血”、“致命性出血”和“大量输血”进行标准化定义，以确保患者分类和治疗策略的一致性。其次，必须采用考虑患者异质性的个体化方法，包括仔细选择目标人群和使用适当的主要终点。第三，在急诊研究环境中必须进行方法学调整，例如实施延迟知情同意程序、进行期中分析以及使用自动化裁决系统，以提高客观性和试验效率。总之，统一术语、接受临床多样性并完善试验设计，对于提高大出血研究的质量、可比性和临床相关性至关重要。这些措施的最终目标是改善危重出血患者的预后。

### 第二部分 AI 大师评价

本文是一篇基于重症监护临床试验专家（3CT）研讨会共识的观点文章，旨在应对致命性出血临床试验中因定义不一和患者异质性带来的挑战。文章提炼出三大核心建议：统一关键术语的标准化定义、针对患者异质性采取个体化研究策略、以及在急诊研究中采用延迟知情同意等创新方法学。该文的价值在于为未来该领域的大型临床研究提供了清晰的方法学指导框架，通过强调标准化与设计的严谨性，有望显著提升研究质量与结果的可比性，从而推动更有效的临床干预策略发展。

---

## 17. 遗传与健康社会决定因素：结节病流行病学差异的驱动力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130282](https://pubmed.ncbi.nlm.nih.gov/41130282)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41130282
**DOI：** 10.1055/a-2724-5501

### 第一部分 原文与翻译

**英文原标题：** Genetics and Social Determinants of Health as Drivers of Epidemiologic Variation in Sarcoidosis.

**英文摘要原文：**
Sarcoidosis is a disease with high morbidity that has variable epidemiology based on genetics and sociodemographic factors. The etiology of this variability remains incompletely understood. This narrative review describes how genetics, social determinants of health, and the interactions between them may contribute to the differences in epidemiology and health outcomes observed in different patient groups with sarcoidosis.

**中文摘要译文：**
结节病是一种高发病率的疾病，其流行病学特征因遗传和社会人口学因素而异。这种差异的病因学基础仍未被完全阐明。这篇叙述性综述旨在阐述遗传学、健康的社会决定因素以及它们之间的相互作用，如何共同导致了在不同结节病患者群体中观察到的流行病学和健康结局的差异。

### 第二部分 AI 大师评价

本文是一篇叙述性综述，其核心目的在于探讨遗传因素与健康的社会决定因素（SDoH）及其相互作用如何共同驱动结节病的流行病学差异。文章通过整合现有研究，系统性地分析了这两个层面的因素对不同患者群体疾病发生率和健康结局的影响。其创新价值在于提供了一个超越单一病因学的综合视角，强调了基因与环境社会因素交互作用在复杂疾病发病机制中的重要性。该综述为理解结节病的病因差异提供了理论框架，并为未来精准预防和干预策略的制定指明了方向。

---

## 18. 21世纪医学的批判性思维——超越疾病脚本

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40996738](https://pubmed.ncbi.nlm.nih.gov/40996738)
**期刊：** JAMA
**PMID：** 40996738
**DOI：** 10.1001/jama.2025.14901

### 第一部分 原文与翻译

**英文原标题：** Critical Thinking for 21st-Century Medicine-Moving Beyond Illness Scripts.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文可能是一篇观点性文章，旨在倡导医学实践和教育的思维范式转变。文章的核心论点是，面对21世纪日益复杂的医疗环境，医生需要超越传统的“疾病脚本”式诊断模式，转向更为系统和深入的批判性思维。由于没有摘要，本文可能侧重于理论探讨，论证在临床决策中整合不确定性、评估证据和进行复杂问题分析的重要性。发表于JAMA这样的顶级期刊，该文的观点对启发医学教育改革、培养新一代医师的核心能力具有重要的指导意义和影响力。

---

## 19. 在内毒素血症诱导的休克模型中，内皮细胞STING和STAT1介导IL-6的IFN非依赖性效应。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40956626](https://pubmed.ncbi.nlm.nih.gov/40956626)
**期刊：** The Journal of clinical investigation
**PMID：** 40956626
**DOI：** 10.1172/JCI189570

### 第一部分 原文与翻译

**英文原标题：** Endothelial STING and STAT1 mediate IFN-independent effects of IL-6 in an endotoxemia-induced model of shock.

**英文摘要原文：**
Severe systemic inflammatory reactions, including sepsis, often lead to shock, organ failure, and death, in part through an acute release of cytokines that promote vascular dysfunction. However, little is known about the vascular endothelial signaling pathways regulating the transcriptional profile in failing organs. Our work focused on signaling downstream of IL-6, due to its clinical importance as a biomarker for disease severity and predictor of mortality. Here, we show that loss of endothelial expression of the IL-6 pathway inhibitor SOCS3 promoted a type I IFN-like (IFNI-like) gene signature in response to endotoxemia in mouse kidneys and brains. In cultured primary human endothelial cells, IL-6 induced transient IFNI-like gene expression in a noncanonical, IFN-independent fashion. We further show that STAT3, which we had previously demonstrated to control IL-6-driven endothelial barrier function, was dispensable for this activity. Instead, IL-6 promoted a transient increase in cytosolic mitochondrial DNA and required STAT1, cGAS, STING, and IRF1, -3, and -4. Inhibition of this pathway in endothelial cell-specific STING-KO mice or global STAT1-KO mice led to reduced the severity of the response to acute endotoxemic challenge and prevented expression of an endotoxin-induced IFNI-like gene signature. These results suggest that permeability and DNA-sensing responses are driven by parallel pathways downstream of this cytokine, provide potential insights into the complex response to acute inflammatory responses, and offer the possibility of novel therapeutic strategies for independently controlling the intracellular responses to IL-6 in order to tailor the inflammatory response.

**中文摘要译文：**
严重的全身性炎症反应（包括脓毒症）常导致休克、器官衰竭和死亡，其部分原因在于急性释放的细胞因子促进了血管功能障碍。然而，关于调控衰竭器官中转录谱的血管内皮信号通路，我们知之甚少。我们的工作聚焦于IL-6的下游信号传导，因其作为疾病严重程度的生物标志物和死亡率预测指标具有重要的临床意义。在此，我们证明在内毒素血症反应中，小鼠肾脏和大脑中内皮细胞IL-6通路抑制剂SOCS3的表达缺失，促进了一种I型干扰素样（IFNI-like）基因特征的出现。在培养的原代人内皮细胞中，IL-6以一种非经典、不依赖IFN的方式诱导了短暂的IFNI-like基因表达。我们进一步表明，我们先前已证明可控制IL-6驱动的内皮屏障功能的STAT3，对于此项活动并非必需。相反，IL-6促进了胞质线粒体DNA的短暂增加，并需要STAT1、cGAS、STING以及IRF1、-3和-4的参与。在内皮细胞特异性STING基因敲除（KO）小鼠或全身性STAT1-KO小鼠中抑制该通路，可减轻对急性内毒素血症攻击的反应严重程度，并阻止内毒素诱导的IFNI-like基因特征的表达。这些结果表明，通透性和DNA感应反应是由该细胞因子下游的平行通路驱动的，为理解对急性炎症反应的复杂应答提供了潜在见解，并为独立控制IL-6的胞内反应以定制炎症反应的新型治疗策略提供了可能性。

### 第二部分 AI 大师评价

本研究旨在揭示在内毒素血症诱导的休克中，白细胞介素-6（IL-6）如何调控血管内皮细胞的炎症反应。通过结合内毒素血症小鼠模型和体外原代人内皮细胞实验，研究团队发现IL-6能通过一条非经典的、不依赖干扰素（IFN）的信号通路诱导I型干扰素样基因表达。关键发现是，此效应不依赖于经典的STAT3，而是由cGAS-STING介导的胞质DNA感应激活STAT1所驱动。该研究的创新之处在于，它明确区分了IL-6下游驱动血管通透性（STAT3依赖）和炎症基因表达（STING/STAT1依赖）的两个平行通路，这为开发更精准的、选择性靶向IL-6有害效应的治疗策略提供了新的分子靶点和理论依据，具有重要的临床转化潜力。

---

## 20. IGFBP6通过Prohibitin-2介导的免疫抑制在小鼠脓毒症中主导抗感染免疫崩溃

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40892465](https://pubmed.ncbi.nlm.nih.gov/40892465)
**期刊：** The Journal of clinical investigation
**PMID：** 40892465
**DOI：** 10.1172/JCI184721

### 第一部分 原文与翻译

**英文原标题：** IGFBP6 orchestrates antiinfective immune collapse in murine sepsis via prohibitin-2-mediated immunosuppression.

**英文摘要原文：**
The persistent challenge of sepsis-related mortality underscores the necessity for deeper insights. Our multicenter, cross-age cohort study identified insulin-like growth factor binding protein 6 (IGFBP6) as a critical regulator in sepsis diagnosis, prognosis, and mortality risk evaluation. Mechanistically, IGFBP6 engages in IGF-independent binding to prohibitin2 (PHB2) on epithelial cells, driving PHB2 tyrosine phosphorylation during sepsis. This process disrupts STAT1 phosphorylation, nuclear translocation, and its recruitment to the CCL2 promoter, ultimately impairing CCL2 transcription and macrophage chemotaxis. Crucially, PHB2 silencing via siPHB2 and STAT1 activation using 2-NP restored CCL2 expression in vitro and in vivo, improving bacterial clearance and survival in septic mice. Concurrently, IGFBP6 compromised macrophage bactericidal activity by inhibiting Akt phosphorylation, reducing ROS/IL-1β production and phagocytic capacity - defects reversible by Akt agonist SC79. Collectively, IGFBP6 emerges as an endogenous driver of sepsis pathogenesis, positioning it as a dual diagnostic biomarker and therapeutic target. Intervention strategies targeting IGFBP6-mediated signaling may offer transformative approaches for sepsis management.

**中文摘要译文：**
脓毒症相关死亡率的持续挑战凸显了深入探究其发病机制的必要性。我们的多中心、跨年龄队列研究发现，胰岛素样生长因子结合蛋白6（IGFBP6）是脓毒症诊断、预后和死亡风险评估中的一个关键调节因子。从机制上讲，IGFBP6以不依赖IGF的方式与上皮细胞上的抑制素2（PHB2）结合，在脓毒症期间驱动PHB2的酪氨酸磷酸化。这一过程干扰了STAT1的磷酸化、核转位及其在CCL2启动子上的招募，最终损害了CCL2的转录和巨噬细胞的趋化作用。关键的是，通过siPHB2沉默PHB2以及使用2-NP激活STAT1，在体内外均恢复了CCL2的表达，从而改善了脓毒症小鼠的细菌清除率和存活率。同时，IGFBP6通过抑制Akt磷酸化，降低了ROS/IL-1β的产生和吞噬能力，从而损害了巨噬细胞的杀菌活性——这些缺陷可通过Akt激动剂SC79逆转。总而言之，IGFBP6是脓毒症发病机制的内源性驱动因素，这使其成为一个具有双重价值的诊断生物标志物和治疗靶点。靶向IGFBP6介导的信号通路的干预策略可能为脓毒症的治疗提供变革性的方法。

### 第二部分 AI 大师评价

本研究通过多中心临床队列与小鼠模型，旨在揭示胰岛素样生长因子结合蛋白6（IGFBP6）在脓毒症免疫抑制中的关键作用。研究团队创新性地发现，IGFBP6通过与上皮细胞的PHB2结合，破坏了STAT1/CCL2信号轴，从而抑制巨噬细胞趋化并削弱其杀菌功能。该研究不仅阐明了脓毒症免疫麻痹的一个全新分子机制，更将IGFBP6定位为一个兼具诊断预后价值和治疗潜力的双重靶点，为开发脓毒症新疗法提供了重要依据和方向。

---

## 21. 髓过氧化物酶锚定的ENO1在脓毒症期间通过IFITM2介导中性粒细胞外诱捕网DNA以增强Treg分化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40892462](https://pubmed.ncbi.nlm.nih.gov/40892462)
**期刊：** The Journal of clinical investigation
**PMID：** 40892462
**DOI：** 10.1172/JCI183541

### 第一部分 原文与翻译

**英文原标题：** Myeloperoxidase-anchored ENO1 mediates neutrophil extracellular trap DNA to enhance Treg differentiation via IFITM2 during sepsis.

**英文摘要原文：**
Sepsis is a life-threatening disease caused by a dysfunctional host response to infection. During sepsis, inflammation-related immunosuppression is the critical factor causing secondary infection and multiple organ dysfunction syndrome. The regulatory mechanisms underlying Treg differentiation and function, which significantly contribute to septic immunosuppression, require further clarification. In this study, we found that neutrophil extracellular traps (NETs) participated in the development of sepsis-induced immunosuppression by enhancing Treg differentiation and function via direct interaction with CD4+ T cells. Briefly, NETs anchored enolase 1 (ENO1) on the membrane of CD4+ T cells through its key protein myeloperoxidase (MPO) and subsequently recruited interferon-induced transmembrane protein 2 (IFITM2). IFITM2 acted as a DNA receptor that sensed NET-DNA and activated intracellular RAS-associated protein 1B (RAP1B) and its downstream ERK signaling pathway to promote Treg differentiation and function. ENO1 inhibition significantly attenuated NET-induced Treg differentiation and alleviated sepsis in mice. Overall, we demonstrated the role of NETs in sepsis-induced immunosuppression by enhancing Treg differentiation, identified ENO1 as an anchor of NET-MPO, and elucidated the downstream molecular mechanism by which IFITM2-RAP1B-ERK regulates Treg differentiation. These findings improve our understanding of the immunopathogenesis of sepsis and provide potential therapeutic targets for sepsis-induced immunosuppression.

**中文摘要译文：**
脓毒症是一种由宿主对感染的反应失调引起的危及生命的疾病。在脓毒症期间，与炎症相关的免疫抑制是导致继发性感染和多器官功能障碍综合征的关键因素。调节性T细胞（Treg）的分化和功能调控机制对脓毒症免疫抑制有重要影响，但仍需进一步阐明。本研究发现，中性粒细胞外诱捕网（NETs）通过与CD4+ T细胞直接相互作用，增强Treg分化和功能，从而参与脓毒症诱导的免疫抑制的发生发展。简而言之，NETs通过其关键蛋白髓过氧化物酶（MPO）将烯醇化酶1（ENO1）锚定在CD4+ T细胞膜上，并随后招募干扰素诱导的跨膜蛋白2（IFITM2）。IFITM2作为一种DNA受体，感知NET-DNA并激活细胞内的RAS相关蛋白1B（RAP1B）及其下游的ERK信号通路，从而促进Treg的分化和功能。抑制ENO1能显著减弱NET诱导的Treg分化，并缓解小鼠的脓毒症。总体而言，我们证明了NETs通过增强Treg分化在脓毒症诱导的免疫抑制中的作用，确定了ENO1是NET-MPO的锚定蛋白，并阐明了IFITM2-RAP1B-ERK调控Treg分化的下游分子机制。这些发现加深了我们对脓毒症免疫发病机制的理解，并为脓毒症诱导的免疫抑制提供了潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示脓毒症期间中性粒细胞外诱捕网（NETs）如何加剧免疫抑制。研究团队通过细胞和动物实验，创新性地发现NETs通过其MPO蛋白将ENO1锚定在T细胞表面，进而招募IFITM2作为DNA受体，激活RAP1B-ERK信号通路，最终促进了抑制性Treg细胞的分化。这一发现不仅深刻阐明了脓毒症免疫抑制的一个关键分子机制，更将ENO1和IFITM2确立为极具潜力的药物靶点，为治疗脓毒症相关免疫功能障碍开辟了新思路。

---

## 22. 在肺纤维化中，髓系-间充质串扰通过鸟氨酸驱动ARG1依赖性的促纤维化代谢

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40875483](https://pubmed.ncbi.nlm.nih.gov/40875483)
**期刊：** The Journal of clinical investigation
**PMID：** 40875483
**DOI：** 10.1172/JCI188734

### 第一部分 原文与翻译

**英文原标题：** Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis.

**英文摘要原文：**
Idiopathic pulmonary fibrosis (IPF) is a disease of progressive lung remodeling and collagen deposition that leads to respiratory failure. Myeloid cells are abundant in IPF lung and in murine lung fibrosis, but their functional effects are incompletely understood. Using mouse and human lung models, we show that ornithine produced by myeloid cells expressing arginase 1 (ARG1) serves as a substrate for proline and collagen synthesis by lung fibroblasts. The predominant ARG1-expressing myeloid cells in mouse lung were macrophages, but in IPF lung, high-dimensional imaging revealed ARG1 was expressed mainly in neutrophils. Small-molecule ARG1 inhibition suppressed both ornithine levels and collagen expression in cultured, precision-cut IPF lung slices and in murine lung fibrosis. These results were confirmed in macrophage-specific Arg1-KO mice. Furthermore, we found that this pathway is regulated by cell-to-cell crosstalk, starting with purinergic signaling: extracellular ATP receptor P2RX4 was necessary for fibroblast IL-6 expression, which, in turn, was necessary for ARG1 expression by myeloid cells. Taken together, our findings define an immune-mesenchymal circuit that governs profibrotic metabolism in lung fibrosis.

**中文摘要译文：**
特发性肺纤维化（IPF）是一种以进行性肺重塑和胶原沉积为特征，并最终导致呼吸衰竭的疾病。在IPF患者肺部和鼠类肺纤维化模型中，髓系细胞数量丰富，但其功能性作用尚未被完全阐明。通过使用小鼠和人类肺部模型，我们证明了表达精氨酸酶1（ARG1）的髓系细胞产生的鸟氨酸，可作为肺成纤维细胞合成脯氨酸和胶原蛋白的底物。在小鼠肺中，主要表达ARG1的髓系细胞是巨噬细胞，但在IPF患者肺中，高维成像技术揭示ARG1主要表达于中性粒细胞。在培养的IPF精准切割肺片和鼠类肺纤维化模型中，使用小分子ARG1抑制剂能够抑制鸟氨酸水平和胶原蛋白的表达。这些结果在巨噬细胞特异性Arg1基因敲除（KO）小鼠中得到了证实。此外，我们发现该通路受到细胞间串扰的调控，起始于嘌呤能信号传导：细胞外ATP受体P2RX4是成纤维细胞表达IL-6所必需的，而IL-6的表达反过来又是髓系细胞表达ARG1所必需的。综上所述，我们的研究结果明确了一个在肺纤维化中调控促纤维化代谢的免疫-间充质回路。

### 第二部分 AI 大师评价

该研究旨在阐明肺纤维化中髓系与间充质细胞串扰驱动纤维化的具体机制。研究综合运用了鼠类模型、人肺组织切片及高维成像技术，关键性地发现了一条由嘌呤能信号（P2RX4）启动，经成纤维细胞IL-6介导，最终驱动髓系细胞（小鼠中为巨噬细胞，人源为中性粒细胞）表达ARG1的信号通路。该通路通过产生鸟氨酸为胶原合成提供原料，从而加剧纤维化。此项研究不仅精准揭示了一个全新的免疫-间充质调控回路，还指出了ARG1作为治疗肺纤维化的潜在靶点，具有重要的科研价值和临床转化潜力。

---

## 23. 高碳酸血症促进小鼠气道和血管的适应不良性重塑

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40857108](https://pubmed.ncbi.nlm.nih.gov/40857108)
**期刊：** The Journal of clinical investigation
**PMID：** 40857108
**DOI：** 10.1172/JCI196928

### 第一部分 原文与翻译

**英文原标题：** Hypercapnia promotes maladaptive airway and vascular remodeling in mice.

**英文摘要原文：**
CO2 isn't just a gas-it can remodel lungs and worsen COPD, but may be reversible with CO2-lowering therapies.

**中文摘要译文：**
二氧化碳不仅仅是一种气体——它可以重塑肺部并加重慢性阻塞性肺疾病（COPD），但通过降低二氧化碳的疗法可能可以逆转这一过程。

### 第二部分 AI 大师评价

本研究通过小鼠模型，探讨了高碳酸血症在肺部疾病进展中的直接作用。研究核心发现，二氧化碳（CO2）不仅仅是代谢废物，它能主动诱导气道和血管的适应不良性重塑，从而可能加剧慢性阻塞性肺疾病（COPD）等病理过程。该研究的创新之处在于揭示了CO2的信号分子角色，并提示降低CO2水平可能成为一种可逆转肺部损伤的潜在治疗策略，为COPD的防治提供了新的视角和靶点。

---

速递结束，祝您工作愉快！